Boston Scientific (BSX)
(Delayed Data from NYSE)
$74.50 USD
-0.66 (-0.88%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $74.50 0.00 (0.00%) 4:40 PM ET
2-Buy of 5 2
C Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$74.50 USD
-0.66 (-0.88%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $74.50 0.00 (0.00%) 4:40 PM ET
2-Buy of 5 2
C Value C Growth B Momentum C VGM
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
Merit Medical (MMSI) Q2 Earnings & Revenues Beat, '24 View Up
by Zacks Equity Research
Merit Medical's (MMSI) second-quarter results reflect growth in earnings and revenues. Operating margin expands.
BD (BDX) Q3 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
BD's (BDX) overall topline benefits from revenue growth in all segments in the fiscal third quarter.
Avanos (AVNS) Q2 Earnings Top Estimates, Gross Margin Contracts
by Zacks Equity Research
Strength in Avanos' (AVNS) Digestive Health segment drives its second-quarter performance.
QuidelOrtho (QDEL) Q2 Earnings Beat Estimates, U.S. Sales Down
by Zacks Equity Research
QuidelOrtho's (QDEL) second-quarter results reflect growth in revenues. However, gross profit continues to decline.
Medtronic Stock Moves Above 50-Day SMA: Should You Buy MDT?
by Urmimala Biswas
Medtronic's (MDT) stock finally breaking above its 50-day SMA can be a piece of good news for investors, signaling an uptrend.
Are Options Traders Betting on a Big Move in Boston Scientific (BSX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Boston Scientific (BSX) stock based on the movements in the options market lately.
Glaukos (GKOS) Q2 Earnings In Line, Glaucoma Drives Sales
by Zacks Equity Research
Glaukos' (GKOS) second-quarter 2024 results showcase growth in revenues on the back of strong adoption of its glaucoma products like iStent and iDose TR. Loss at the operating level raises concern.
Cencora (COR) Q3 Earnings Beat Estimates, '24 View Raised
by Zacks Equity Research
Cencora's (COR) third-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.
Boston Scientific (BSX) Rides on Global Growth, Buyouts
by Zacks Equity Research
Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.
Inari Medical (NARI) Q2 Earnings Miss, Revenues Increase Y/Y
by Zacks Equity Research
Inari Medical's (NARI) second-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the company continues to incur operating losses.
GE HealthCare (GEHC) Q2 Earnings Beat Estimates, Net Margin Up
by Zacks Equity Research
GE HealthCare's (GEHC) second-quarter results witness declining segmental revenues in imaging, ultrasound and patient care. The bottom line improves on better pricing.
DENTSPLY SIRONA (XRAY) Q2 Earnings Miss, Revenues Decline Y/Y
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) second-quarter 2024 results showcase a year-over-year decline in earnings as well as sales.
Fresenius Medical (FMS) Q2 Earnings In Line, Operating Margin Up
by Zacks Equity Research
Fresenius Medical's (FMS) second-quarter revenues suffer due to divestures. However, the company???s transformational plans continue to benefit its operating income.
Ecolab (ECL) Q2 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Ecolab's (ECL) robust performance across the majority of its segments drives its second-quarter sales amid business challenges.
Revvity (RVTY) Q2 Earnings Beat Estimates, Guidance Revised
by Zacks Equity Research
Revvity's (RVTY) second-quarter results showcase a decline in life sciences segmental revenues.
Integer Holdings (ITGR) Q2 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Integer Holdings' (ITGR) second-quarter results reflect robust Medical Sales, along with strength in all the product lines.
3 Reasons Why You Should Hold HealthEquity (HQY) Stock Now
by Zacks Equity Research
HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.
Three Reasons to Retain Avanos (AVNS) Stock in Your Portfolio
by Zacks Equity Research
Avanos' (AVNS) strong product line and focus on R&D raise optimism about the stock.
Alphatec's (ATEC) New EOS Insight System to Boost Spine Care
by Zacks Equity Research
Alphatec (ATEC) announces the commercial launch of its EOS Insight, an end-to-end spine surgery platform powered by standardized EOSedge scans and artificial intelligence.
Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
Boston Scientific (BSX) Q2 Earnings Beat, Organic Sales Rise
by Zacks Equity Research
Boston Scientific (BSX) registers a strong year-over-year improvement in sales, indicating solid market share gains in legacy businesses across all geographic regions.
Veeva Systems' (VEEV) Vault EDC to Boost Vita Global's Workflow
by Zacks Equity Research
Veeva Systems' (VEEV) Vault EDC is likely to aid the CRO in delivering a better experience to patients, research sites and sponsors.
PacBio's (PACB) Revio System to Boost Novogene's German Lab
by Zacks Equity Research
PacBio (PACB) announces that Novogene is set to use PACB's Revio long-read sequencing system to expand the capabilities of its new lab in Munich, Germany.
Boston Scientific (BSX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Boston Scientific (BSX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
The Zacks Analyst Blog Highlights Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences
by Zacks Equity Research
Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences are part of the Zacks Top Analyst Blog.